Specific self-reactive antibodies are associated with different symptoms and complications in people with systemic sclerosis (SSc) without overlap syndrome, a study in Brazil shows. For instance, autoantibodies targeting Scl70 or centromere were tied to differences in when the disease starts, how the skin is affected, and the risk of…
News
Some people with systemic sclerosis (SSc) have autoimmune hepatitis (AIH), a condition marked by liver inflammation caused by self-reactive antibodies, a study in Turkey shows. The study also identified the blood levels of the liver enzyme alanine aminotransferase (ALT) as the most accurate predictor of AIH. “Our findings highlight…
Autologous stem cell transplant (ASCT), a procedure that essentially aims to reset the immune system, was effective for controlling scleroderma in a teenager with severe disease that wasn’t responding well to medications. “ASCT may represent an important therapeutic option, particularly perhaps in patients who develop severe disease at a…
Through an analysis of genetic data, scientists have identified dozens of existing medications that could potentially be repurposed as treatments for scleroderma, according to a new study. Potential treatments identified in the analysis include therapies that modulate the activity of estrogen, a female sex hormone, as well as medicines…
Measuring the blood levels of anti-CD146 antibodies may help identify people with systemic sclerosis (SSc) whose disease is associated with occupational exposure to silica and other mineral dusts, according to a small study. This is the first biomarker linked to occupational exposure identified in SSc. Detecting these antibodies…
Treatment with AISA-021 (cilnidipine), being developed by Aisa Pharma for Raynaud’s phenomenon, safely reduced the frequency and duration of Raynaud’s attacks in people with systemic sclerosis (SSc). That’s according to recently reported results from the Phase 2 RECONNOITER-1 trial (ACTRN12621000459820) — data that also showed that the…
Hand baths enriched with carbon dioxide (CO2) — a gas that exists naturally in the atmosphere, and is produced by living things breathing out — can significantly widen blood vessels of the fingers in people with systemic sclerosis (SSc)-associated Raynaud’s phenomenon. That’s according to a small clinical trial…
The use of immunosuppressive and combination treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD) has increased significantly over the past two decades, with more than half of patients now starting treatment at their first evaluation, according to a new study. Over the same period, rates of…
Levels of soluble CD13, the circulating form of a protein involved in inflammation and fibrosis (scarring), are generally higher in people with scleroderma, but do not clearly correlate with disease severity or specific clinical features, a new study reports. The findings suggest that CD13 alone is unlikely to serve…
Mesenchymal stem cells (MSCs) — a type of regulatory cell found in various tissues — work to reduce lung scarring in systemic sclerosis (SSc) by suppressing the growth of certain immune T-cells that carry the PD-1 receptor, according to a new study. PD-1 is an immune checkpoint protein…
Recent Posts
- Trial to test scleroderma treatments at earliest stages of disease
- Off-label JAK inhibitors may stabilize lung function in systemic sclerosis
- Distinct symptom pattern found for triple-negative scleroderma patients
- Plant-based nanoparticle therapy eases skin thickening in SSc: Study
- Specialized MRI scans may catch early lung damage in scleroderma
- Spotlighting ‘Beacons of Hope’ for this year’s Scleroderma Awareness Month
- Fewer capillaries in hands may contribute to scleroderma bone loss
- New scleroderma therapy BLR-200 shows potential to prevent scarring
- Signaling pathway in skin cells may drive scleroderma inflammation
- Genetic links to systemic sclerosis may differ by sex, new study finds